A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer

Abstract The objective of this multicenter, single‐arm trial (ChiCTR1900022293) was to explore the efficacy and safety of neoadjuvant therapy with epirubicin, cyclophosphamide, and pyrotinib followed by docetaxel, trastuzumab, and pyrotinib (ECPy‐THPy) in the treatment of patients with stage II–III...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Qiyun Shi, Xiaowei Qi, Peng Tang, Linjun Fan, Li Chen, Shushu Wang, Yan Liang, Ying Hu, Minghao Wang, Lin Ren, Guozhi Zhang, Xuanni Tan, Long Yuan, Junze Du, Xiujuan Wu, Mengyuan Wang, Hongying Che, Pengwei Lv, Dejie Chen, Jinhui Hu, Qiuyun Li, Yanwu Zhang, Kunxian Yang, Yuan Zhong, Chuang Chen, Zemin Zhou, Liyuan Qian, Jingwei Zhang, Mingde Ma, Yi Sun, Yi Zhang, Jun Jiang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2023-12-01
Edice:	MedComm
Témata:	HER2‐positive breast cancer multicenter study neoadjuvant therapy pyrotinib trastuzumab
On-line přístup:	https://doi.org/10.1002/mco2.435
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!